Stockscreener 앱 받기
3.02
2.27%
-0.07
시간 외 거래:
3.03
0.010
+0.33%
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Stocktwits
Elicio Therapeutics (NASDAQ:ELTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Elicio Therapeutics (ELTX) Stock Forum and Discussion - Moomoo
Elicio Therapeutics: Q2 Earnings Snapshot - AOL.com
Elicio Therapeutics Q2 Results: EPS beats estimate, losses narrow 35% YoY - scanx.trade
Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results - MarketBeat
Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss - Stock Titan
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall - TradingView
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma - The Manila Times
Elicio Therapeutics Announces Opening of MSK-Led Phase 1 Neoadjuvant Study of ELI-002 7P in Resectable Pancreatic Cancer - Quiver Quantitative
Elicio Therapeutics Announces Activation of the - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
ELTX Q2'26 Earnings: EPS estimate is (0.54) USD - TradingView
(ELTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Certain Stock Options of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com
Certain Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com
Elicio Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
ELTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Elicio Therapeutics (ELTX) Expected to Post Earnings on Thursday - MarketBeat
Elicio Therapeutics (NASDAQ:ELTX) Stock Price Down 1.7%Here's What Happened - MarketBeat
Price to sales ratio of Elicio Therapeutics, Inc – HAM:9HA - TradingView
Elicio Therapeutics Inc (ELTX) Cash Flow - TradingKey
ELTX|Elicio Therapeutics Inc|Price:3.000| - TradingKey
Elicio Therapeutics Inc (ELTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Elicio Therapeutics Inc (ELTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elicio Therapeutics Market Sentiment - Benzinga
Elicio Therapeutics Inc (ELTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Elicio Therapeutics Inc (ELTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ELTX|Elicio Therapeutics Inc|Price:3.000|Chg%:-0.150 - TradingKey
TradingKey - TradingKey
Elicio Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELTX - TradingView
Elicio Therapeutics Inc (ELTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Form 4 Elicio Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Ladenburg Thalmann initiates coverage of Elicio Therapeutics (ELTX) with buy recommendation - MSN
Elicio Therapeutics (ELTX) awards 64,643 stock options to R&D and medical chief - Stock Titan
Elicio Therapeutics (ELTX) grants 52,832 stock options to Chief Scientific Officer - Stock Titan
Elicio Therapeutics (ELTX) awards 60,833 stock options to its CFO - Stock Titan
Elicio Therapeutics (ELTX) CEO awarded 186,944 stock options at 3.2000 - Stock Titan
Moti Investments discloses 6.1% stake in Elicio Therapeutics (NASDAQ: ELTX) - Stock Titan
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Price-Driven Insight from (ELTX) for Rule-Based Strategy - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Connect - ACCESS Newswire
Enterprise value to revenue forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX - TradingView
ELTX Stock Price, Quote & Chart - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Reach Out - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc.ELTX - PR Newswire
Why Is ELTX Stock Falling Today? - Stocktwits
[SCHEDULE 13G/A] Elicio Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-07-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Shareholders to Learn More About the Investigation | NDAQ:ELTX | Press Release - Stockhouse
Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
ELICIO THERAPEUTICS ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING - Moomoo
Elicio Therapeutics closes $15 million stock offering - Investing.com
Elicio Therapeutics Closes $15 Million Registered Direct Offering - marketscreener.com
Elicio Therapeutics closes $15 million stock offering By Investing.com - Investing.com South Africa
1.80%
1.77%
자본화:
|
볼륨(24시간):